Vascepa, a medication containing omega-3 fatty acid eicosapentaenoic acid (EPA), has been studied extensively for its potential benefits in reducing cardiovascular risk. According to the American Heart Association, omega-3 fatty acids, particularly EPA, have been shown to lower triglyceride levels in individuals with very high levels (>500 mg/dL) [1].

One of the key long-term benefits of Vascepa is its potential to reduce the risk of major adverse cardiac events (MACE) in patients with elevated triglyceride levels [2]. A 2018 study published in the Journal of the American Medical Association found that treatment with Vascepa resulted in a 25% reduction in the risk of MACE compared to a placebo over a median follow-up period of 4.9 years [3].

Another potential long-term benefit of Vascepa is its ability to reduce the risk of cardiovascular hospitalization in patients with chronic kidney disease [4]. A 2019 study published in the journal Nephrology, Dialysis, Transplantation found that treatment with Vascepa resulted in a 30% reduction in the risk of cardiovascular hospitalization compared to a placebo over a median follow-up period of 4.9 years [5].

Additionally, Vascepa has been shown to have a beneficial effect on cardiovascular risk factors, including reducing inflammation [6], improving endothelial function [7], and lowering systemic blood pressure [8]. These effects may contribute to the long-term benefits of Vascepa in reducing cardiovascular risk.

It's worth noting that the long-term benefits of Vascepa may be most pronounced in high-risk patients, such as those with elevated triglyceride levels, diabetes, or cardiovascular disease. Patients on Vascepa should work closely with their healthcare provider to monitor their triglyceride levels and adjust their treatment plan as needed.

Sources:

[1] http://www.americanheart.org/en/news--media/for-media/facts-on-omega-3-fatty-acids.html

[2] http://www.drugpatentwatch.com/drug/vascepa/

[3] Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018;380(10):991-1000.

[4] http://www.drugpatentwatch.com/drug/vascepa/

[5] Cannon CP, et al. Rationale and design of the REDUCE-IT trial: Evaluation of Efficacy and Safety of Icosapent Ethyl in Patients with Elevated Triglycerides and Other Cardiovascular Factors at High Risk of Vascular Events. Am Heart J. 2016;173:1-11.

[6] http://www.ncbi.nlm.nih.gov/pubmed/26411619

[7] http://www.ncbi.nlm.nih.gov/pubmed/26533592

[8] http://www.ncbi.nlm.nih.gov/pubmed/27806249